Another batch of drugs passed the consistency evaluation, and more than 200 varieties have been evaluated in 2022!

On March 10, Sinopharm issued an announcement on the consistency evaluation of its subsidiary drugs through generic drugs
.
The announcement shows that the risedronate sodium tablets of Tianfang Co.
, Ltd.
, a wholly-owned subsidiary of the company, passed the quality and efficacy consistency evaluation of generic drugs
.
It is reported that risedronate sodium tablets is a bone resorption inhibitor, suitable for the treatment and prevention of osteoporosis in postmenopausal women
.
As of the disclosure date of the announcement, the R&D investment in the consistency evaluation of the drug was approximately RMB 8.
44 million (unaudited)
.
Relevant data shows that in the first three quarters of 2021, the sales of domestic sample hospitals are about 14.
72 million yuan
.
The company's unaudited sales revenue of the drug in 2021 is about 165,300 yuan
.
As of the disclosure date of this announcement, one domestic company, Yangtze River Pharmaceuticals, has passed the consistency evaluation of this variety
.
Fangsheng Pharmaceutical also issued an announcement on the evening of March 8 that cefixime tablets passed the quality and efficacy consistency evaluation of generic drugs
.
As of the announcement date, the company has invested about 2.
2454 million yuan (unaudited) in research and development for the consistency evaluation of the drug
.
According to data from Minet.
com, the domestic sales of cefixime oral preparations in 2020 will be about 2.
732 billion yuan
.
In 2021, the sales revenue of cefixime tablets produced by the company will be 39.
82 million yuan
.
Up to now, including Fangsheng Pharmaceutical, a total of 3 manufacturers have passed the consistency evaluation and approval
.
It is understood that in accordance with relevant regulations, drug varieties that have passed the consistency evaluation should be properly supported in medical insurance payment, and medical institutions should give priority to purchasing and selecting them in clinical practice
.
If there are more than three production enterprises that pass the consistency evaluation of the same variety of drugs, the varieties that have not passed the consistency evaluation will no longer be selected for centralized drug procurement
.
In recent years, with the normalization of centralized procurement, pharmaceutical companies have become more active in consistency evaluation
.
Since 2022, in addition to the variety over-reviews of the above-mentioned pharmaceutical companies, there are also a number of drug over-reviews, and there are many leading companies that have over-reviewed.

.
For example, in January, Sihuan Pharmaceutical announced that its antithrombotic drug ticagrelor tablets (60 mg and 90 mg) had been approved for drug registration issued by the State Food and Drug Administration of China, which was deemed a review; Luoxin Pharmaceutical announced that Its subsidiary's meropenem for injection passed the consistency evaluation of generic drugs; Jinhua Conba's subsidiary Jinhua Conba's parecoxib sodium for injection passed the consistency evaluation of generic drugs; "Promethazine Hydrochloride Tablets" passed the evaluation; Atosiban Acetate Injection of Hanyu Pharmaceutical passed the consistency evaluation of generic drugs; Flunarizine Hydrochloride Capsules of Zhendong Pharmaceutical Co.
, Ltd.
passed the consistency evaluation of generic drugs; Shanghai Pharmaceutical Holdings Co.
, Ltd.
The company's Chia Tai Qingchunbao Pharmaceutical Co.
, Ltd.
has reviewed Flunarizine Hydrochloride Capsules
.
In February, the "Notice on Announcement of the First Batch of Generic Drug Quality and Efficacy Consistency Evaluations for Online Purchase in 2022" issued by Shanghai Sunshine Pharmaceutical Purchasing Network showed that a total of 210 products were reviewed and purchased online, involving 122 drugs.
Enterprises, the reviewed varieties include Amoxicillin Capsules of Yuekang Pharmaceutical, Omeprazole Enteric-Coated Tablets of Fangsheng Pharmaceutical, Bicalutamide Tablets of Jianghaizheng Pharmaceutical, etc.
; February 20, 2022 - February 26, 2022 Today, 16 new varieties (deemed) have been reviewed, among which Compound Amino Acid (15) Dipeptide (2) Injection from Kelun Pharmaceutical, Calcitriol Capsule from Chongqing Hemony, and Glucose from Chengdu Beite Four varieties of calcium acid injection and ursodeoxycholic acid tablets of Wuhan Puyuan Pharmaceutical are the first in the country to be reviewed
.
In March, there were also a large number of drug reviews
.
For example, Shanghai Pharmaceuticals announced on March 4 that Flunarizine Hydrochloride Capsules of Shandong Xinyi, a holding subsidiary, passed the consistency evaluation of generic drugs; Levobupivacaine Hydrochloride Injection of Jiangsu Osaikang Pharmaceuticals passed the evaluation, ranking first in China.
2 enterprises that have passed the evaluation; Phloroglucinol injection of Wanbangde Pharmaceutical, a subsidiary of Wanbangde, passed the consistency evaluation
.
In the field of medicines, the company is the first domestic pharmaceutical company to pass the evaluation; Yabao Pharmaceutical recently received the approval notice issued by the State Food and Drug Administration, and the company's methylcobalamin injection passed the quality and efficacy consistency evaluation of generic drugs; Yangzijiang The sodium potassium magnesium sulfate oral solution and levofloxacin sodium chloride injection reported by the pharmaceutical industry as 3/4 generic drugs were approved for marketing, which are deemed to have passed the consistency evaluation
.
According to incomplete statistics, since January 1, 2022, more than 200 varieties have passed the consistency evaluation of generic drugs
.
For pharmaceutical companies that have over-evaluated their products, product over-evaluation will help improve the company's market competitiveness, expand market share, and prepare for centralized procurement
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.